Natural Killer Cell Defects in Breast Cancer: A Key Pathway for Tumor Evasion

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Dai X, Li T, Bai Z, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015;5(10):2929–2943.
   PubMed Web of Science ®Google Scholar
• Cornejo KM, Kandil D, Khan A, et al. Theranostic and molecular classification of breast cancer. Arch Pathol Lab Med. 2014;138(1):44–56. doi:10.5858/arpa.2012-0442-RA.
   PubMed Web of Science ®Google Scholar
• Saraiva DP, Guadalupe Cabral M, Jacinto A, et al. How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. ESMO Open. 2017;2(4):e000208. doi:10.1136/esmoopen-2017-000208.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991–998. doi:10.1038/ni1102-991.
   PubMed Web of Science ®Google Scholar
• Levy EM, Roberti MP, Mordoh J. Natural killer cells in human cancer: from biological functions to clinical applications. J Biomed Biotechnol. 2011;2011:676198.
   PubMedGoogle Scholar
• Hallett WH, Murphy WJ. Positive and negative regulation of natural killer cells: therapeutic implications. Semin Cancer Biol. 2006;16(5):367–382. doi:10.1016/j.semcancer.2006.07.003.
   PubMed Web of Science ®Google Scholar
• Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 1975;16(2):216–229. doi:10.1002/ijc.2910160204.
   PubMed Web of Science ®Google Scholar
• Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. 1975;5(2):112–117. doi:10.1002/eji.1830050208.
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633–640.
   PubMed Web of Science ®Google Scholar
• Anfossi N, André P, Guia S, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006;25(2):331–342. doi:10.1016/j.immuni.2006.06.013.
   PubMed Web of Science ®Google Scholar
• Ferlazzo G, Munz C. NK cell compartments and their activation by dendritic cells. J Immunol. 2004;172(3):1333–1339. doi:10.4049/jimmunol.172.3.1333.
   PubMed Web of Science ®Google Scholar
• Miller JS. The biology of natural killer cells in cancer, infection, and pregnancy. Exp Hematol. 2001;29(10):1157–1168.
   PubMed Web of Science ®Google Scholar
• Cheng M, Chen Y, Xiao W, et al. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol. 2013;10(3):230–252.
   PubMed Web of Science ®Google Scholar
• Carlsten M, Jaras M. Natural killer cells in myeloid malignancies: immune surveillance, NK cell dysfunction, and pharmacological opportunities to bolster the endogenous NK cells. Front Immunol. 2019;10:2357. doi:10.3389/fimmu.2019.02357.
   PubMed Web of Science ®Google Scholar
• Topham NJ, Hewitt EW. Natural killer cell cytotoxicity: how do they pull the trigger? Immunology 2009;128(1):7–15. doi:10.1111/j.1365-2567.2009.03123.x.
   PubMed Web of Science ®Google Scholar
• Martin-Fontecha A, Thomsen LL, Brett S, et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004;5(12):1260–1265.
   PubMed Web of Science ®Google Scholar
• Ames E, Murphy WJ. Advantages and clinical applications of natural killer cells in cancer immunotherapy. Cancer Immunol Immunother. 2014;63(1):21–28. doi:10.1007/s00262-013-1469-8.
   PubMed Web of Science ®Google Scholar
• Kim N, Kim HS. Targeting checkpoint receptors and molecules for therapeutic modulation of natural killer cells. Front Immunol. 2018;9:2041. doi:10.3389/fimmu.2018.02041.
   PubMed Web of Science ®Google Scholar
• Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 2016;44(5):989–1004.
   PubMed Web of Science ®Google Scholar
• Beldi-Ferchiou A, Caillat-Zucman S. Control of NK cell activation by immune checkpoint molecules. Int J Mol Sci. 2017;18(10):2129.
   Web of Science ®Google Scholar
• Beldi-Ferchiou A, Lambert M, Dogniaux S, et al. PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget 2016;7(45):72961–72977. doi:10.18632/oncotarget.12150.
   PubMedGoogle Scholar
• Tabellini G, Benassi M, Marcenaro E, et al. Primitive neuroectodermal tumor in an ovarian cystic teratoma: natural killer and neuroblastoma cell analysis. Case Rep Oncol. 2014;7(1):70–78. doi:10.1159/000357802.
   PubMedGoogle Scholar
• Benson DM, Bakan CE, Mishra A, Jr, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010;116(13):2286–2294. doi:10.1182/blood-2010-02-271874.
   PubMed Web of Science ®Google Scholar
• MacFarlane AW, Jillab M, Plimack ER, et al. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res. 2014;2(4):320–331.
   PubMed Web of Science ®Google Scholar
• Pesce S, Greppi M, Tabellini G, et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. J Allergy Clin Immunol. 2017;139(1):335–346 e3. doi:10.1016/j.jaci.2016.04.025.
   PubMed Web of Science ®Google Scholar
• Ndhlovu LC, Lopez-Vergès S, Barbour JD, et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 2012;119(16):3734–3743.
   PubMed Web of Science ®Google Scholar
• Gleason MK, Lenvik TR, McCullar V, et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 2012;119(13):3064–3072. doi:10.1182/blood-2011-06-360321.
   PubMed Web of Science ®Google Scholar
• Gallois A, Silva I, Osman I, et al. Reversal of natural killer cell exhaustion by TIM-3 blockade. Oncoimmunology 2014;3(12):e946365. doi:10.4161/21624011.2014.946365.
   PubMed Web of Science ®Google Scholar
• Ohs I, Ducimetière L, Marinho J, et al. Restoration of natural killer cell antimetastatic activity by IL12 and checkpoint blockade. Cancer Res. 2017;77(24):7059–7071. doi:10.1158/0008-5472.CAN-17-1032.
   PubMed Web of Science ®Google Scholar
• Sun C, Sun H. The rise of NK cell checkpoints as promising therapeutic targets in cancer immunotherapy. Front Immunol. 2019;10:2354. doi:10.3389/fimmu.2019.02354.
   PubMed Web of Science ®Google Scholar
• Triki H, Charfi S, Bouzidi L, et al. CD155 expression in human breast cancer: clinical significance and relevance to natural killer cell infiltration. Life Sci. 2019;231:116543. doi:10.1016/j.lfs.2019.116543.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19(7):723–732. doi:10.1038/s41590-018-0132-0.
   PubMed Web of Science ®Google Scholar
• Roberti MP, Juliá EP, Rocca YS, et al. Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade. Eur J Immunol. 2015;45(5):1560–1569. doi:10.1002/eji.201445353.
   PubMed Web of Science ®Google Scholar
• Mamessier E, Sylvain A, Thibult M-L, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 2011;121(9):3609–3622. doi:10.1172/JCI45816.
   PubMed Web of Science ®Google Scholar
• Wang N, Calpe S, Westcott J, et al. Cutting edge: the adapters EAT-2A and -2B are positive regulators of CD244- and CD84-dependent NK cell functions in the C57BL/6 mouse. J Immunol. 2010;185(10):5683–5687. doi:10.4049/jimmunol.1001974.
   PubMed Web of Science ®Google Scholar
• Boles KS, Nakajima H, Colonna M, et al. Molecular characterization of a novel human natural killer cell receptor homologous to mouse 2B4. Tissue Antigens 1999;54(1):27–34. doi:10.1034/j.1399-0039.1999.540103.x.
   PubMedGoogle Scholar
• Agresta L, Hoebe KHN, Janssen EM. The emerging role of CD244 signaling in immune cells of the tumor microenvironment. Front Immunol. 2018;9:2809. doi:10.3389/fimmu.2018.02809.
   PubMed Web of Science ®Google Scholar
• Eissmann P, Beauchamp L, Wooters J, et al. Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244). Blood 2005;105(12):4722–4729.
   PubMed Web of Science ®Google Scholar
• Thomas LM, Peterson ME, Long EO. Cutting edge: NK cell licensing modulates adhesion to target cells. J Immunol. 2013;191(8):3981–3985. doi:10.4049/jimmunol.1301159.
   PubMed Web of Science ®Google Scholar
• Nieto-Velazquez NG, Torres-Ramos YD, Muñoz-Sánchez JL, et al. Altered expression of natural cytotoxicity receptors and NKG2D on peripheral blood NK cell subsets in breast cancer patients. Transl Oncol. 2016;9(5):384–391.
   PubMed Web of Science ®Google Scholar
• Lee HH, Cho HJM. Attenuated anti-tumor activity of NK-92 cells by invasive human breast carcinoma MDA-MB-231 cells. Mol Cell Toxicol. 2020;16:139–147.
   Web of Science ®Google Scholar
• Sanchez-Correa B, Valhondo I, Hassouneh F, et al. DNAM-1 and the TIGIT/PVRIG/TACTILE axis: novel immune checkpoints for natural killer cell-based cancer immunotherapy. Cancers 2019;11(6):877.
   PubMed Web of Science ®Google Scholar
• Mamessier E, Sylvain A, Bertucci F, et al. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK-cells recognition. Cancer Res. 2011;71(21):6621–6632.
   PubMed Web of Science ®Google Scholar
• Du X, de Almeida P, Manieri N, et al. CD226 regulates natural killer cell antitumor responses via phosphorylation-mediated inactivation of transcription factor FOXO1. Proc Natl Acad Sci USA. 2018;115(50):E11731–E11740. doi:10.1073/pnas.1814052115.
   PubMed Web of Science ®Google Scholar
• Yong H, Cheng R, Li X, et al. CD155 expression and its prognostic value in postoperative patients with breast cancer. Biomed Pharmacother. 2019;115:108884.
   PubMed Web of Science ®Google Scholar
• Li X-Y, Das I, Lepletier A, et al. CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. J Clin Invest. 2018;128(6):2613–2625. doi:10.1172/JCI98769.
   PubMed Web of Science ®Google Scholar
• Carlsten M, Norell H, Bryceson YT, et al. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol. 2009;183(8):4921–4930. doi:10.4049/jimmunol.0901226.
   PubMed Web of Science ®Google Scholar
• Chester C, Fritsch K, Kohrt HE. Natural killer cell immunomodulation: targeting activating, inhibitory, and co-stimulatory receptor signaling for cancer immunotherapy. Front Immunol. 2015;6:601. doi:10.3389/fimmu.2015.00601.
   PubMed Web of Science ®Google Scholar
• Malhotra A, Shanker A. NK cells: immune cross-talk and therapeutic implications. Immunotherapy 2011;3(10):1143–1166. doi:10.2217/imt.11.102.
   PubMed Web of Science ®Google Scholar
• Ostapchuk YO, Cetin EA, Perfilyeva YV, et al. Peripheral blood NK cells expressing HLA-G, IL-10 and TGF-β in healthy donors and breast cancer patients. Cell Immunol. 2015;298(1–2):37–46. doi:10.1016/j.cellimm.2015.09.002.
   PubMed Web of Science ®Google Scholar
• Mamessier E, Pradel LC, Thibult M-L, et al. Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets. J Immunol. 2013;190(5):2424–2436. doi:10.4049/jimmunol.1200140.
   PubMed Web of Science ®Google Scholar
• Caras I, Grigorescu A, Stavaru C, et al. Evidence for immune defects in breast and lung cancer patients. Cancer Immunol Immunother. 2004;53(12):1146–1152. doi:10.1007/s00262-004-0556-2.
   PubMed Web of Science ®Google Scholar
• Simonetta F, Pradier A, Roosnek E. T-bet and eomesodermin in NK cell development, maturation, and function. Front Immunol. 2016;7:241. doi:10.3389/fimmu.2016.00241.
   PubMed Web of Science ®Google Scholar
• Knox JJ, Cosma GL, Betts MR, et al. Characterization of T-bet and eomes in peripheral human immune cells. Front Immunol. 2014;5:217. doi:10.3389/fimmu.2014.00217.
   PubMed Web of Science ®Google Scholar
• Krneta T, Gillgrass A, Chew M, et al. The breast tumor microenvironment alters the phenotype and function of natural killer cells. Cell Mol Immunol. 2016;13(5):628–639. doi:10.1038/cmi.2015.42.
   PubMed Web of Science ®Google Scholar
• Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7(3):211–217.
   PubMed Web of Science ®Google Scholar
• de Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol. 2006;13:118–137.
   Google Scholar
• Balsamo M, Scordamaglia F, Pietra G, et al. Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci USA. 2009;106(49):20847–20852.
   PubMed Web of Science ®Google Scholar
• Eruslanov E, Daurkin I, Ortiz J, et al. Pivotal advance: tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells. J Leukoc Biol. 2010;88(5):839–848. doi:10.1189/jlb.1209821.
   PubMed Web of Science ®Google Scholar
• Holt D, et al. Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4. J Immunother (Hagerstown, Md.: 1997). 2012;35(2):179.
   PubMed Web of Science ®Google Scholar
• Ma X, Holt D, Kundu N, et al. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis. Oncoimmunology 2013;2(1):e22647. doi:10.4161/onci.22647.
   PubMed Web of Science ®Google Scholar
• Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999;79(4):1193–1226.
   PubMed Web of Science ®Google Scholar
• Ma X, Kundu N, Rifat S, et al. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res. 2006;66(6):2923–2927. doi:10.1158/0008-5472.CAN-05-4348.
   PubMed Web of Science ®Google Scholar
• Holt D, Ma X, Kundu N, et al. Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4. Cancer Immunol Immunother. 2011;60(11):1577–1586. doi:10.1007/s00262-011-1064-9.
   PubMed Web of Science ®Google Scholar
• Sotiropoulou PA, Perez SA, Gritzapis AD, et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006;24(1):74–85. doi:10.1634/stemcells.2004-0359.
   PubMed Web of Science ®Google Scholar
• Levy EM, Roberti MP, Mordoh J. Natural killer cells in human cancer: from biological functions to clinical applications. BioMed Res Int. 2011;2011:1–11.
   Google Scholar
• Pende D, Cantoni C, Rivera P, et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol. 2001;31(4):1076–1086.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105(4):1815–1822. doi:10.1182/blood-2004-04-1559.
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Shah MH, Turner MJ, et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol. 1999;162(8):4511–4520.
   PubMed Web of Science ®Google Scholar
• Lauwerys BR, Garot N, Renauld JC, et al. Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J Immunol. 2000;165(4):1847–1853. doi:10.4049/jimmunol.165.4.1847.
   PubMed Web of Science ®Google Scholar
• Joshi PC, Zhou X, Cuchens M, et al. Prostaglandin E2 suppressed IL-15-mediated human NK cell function through down-regulation of common gamma-chain. J Immunol. 2001;166(2):885–891. doi:10.4049/jimmunol.166.2.885.
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Reclos GJ, Gritzapis AD, et al. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine‐activated killer cell function in patients with breast cancer. Cancer 1993;72(2):491–501.
   PubMed Web of Science ®Google Scholar
• Kundu N, Yang Q, Dorsey R, et al. Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. Int J Cancer. 2001;93(5):681–686. doi:10.1002/ijc.1397.
   PubMed Web of Science ®Google Scholar
• Kundu N, Walser TC, Ma X, et al. Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol Immunother. 2005;54(10):981–987. doi:10.1007/s00262-005-0669-2.
   PubMed Web of Science ®Google Scholar
• Kundu N, Ma X, Holt D, et al. Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Res Treat. 2009;117(2):235–242. doi:10.1007/s10549-008-0180-5.
   PubMed Web of Science ®Google Scholar
• Sheng H, Shao J, Morrow JD, et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998;58(2):362–366.
   PubMed Web of Science ®Google Scholar
• Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60(5):1306–1311.
   PubMed Web of Science ®Google Scholar
• Goodwin JS, Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol. 1983;3(4):295–315. doi:10.1007/BF00915791.
   PubMed Web of Science ®Google Scholar
• Sinha P, Clements VK, Fulton AM, et al. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007;67(9):4507–4513. doi:10.1158/0008-5472.CAN-06-4174.
   PubMed Web of Science ®Google Scholar
• Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol. 2000;164(1):361–370. doi:10.4049/jimmunol.164.1.361.
   PubMed Web of Science ®Google Scholar
• Prendergast G. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008;27(28):3889–3900. doi:10.1038/onc.2008.35.
   PubMed Web of Science ®Google Scholar
• Della Chiesa M, Carlomagno S, Frumento G, et al. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood 2006;108(13):4118–4125. doi:10.1182/blood-2006-03-006700.
   PubMed Web of Science ®Google Scholar
• Frumento G, Rotondo R, Tonetti M, et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med. 2002;196(4):459–468. doi:10.1084/jem.20020121.
   PubMed Web of Science ®Google Scholar
• Pietra G, Manzini C, Rivara S, et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res. 2012;72(6):1407–1415.
   PubMed Web of Science ®Google Scholar
• Wang D, Saga Y, Mizukami H, et al. Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer rian cancer therapy. Int J Oncol. 2012;40(4):929–934. doi:10.3892/ijo.2011.1295.
   PubMed Web of Science ®Google Scholar
• Liu X, Shin N, Koblish HK, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010;115(17):3520–3530. doi:10.1182/blood-2009-09-246124.
   PubMed Web of Science ®Google Scholar
• Soliman H, Rawal B, Fulp J, et al. Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry. Cancer Immunol Immunother. 2013;62(5):829–837. doi:10.1007/s00262-013-1393-y.
   PubMed Web of Science ®Google Scholar
• Madjd Z, Spendlove I, Moss R, et al. Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immun Arch. 2007;7(1):17.
   PubMedGoogle Scholar
• Durrant LG, Chapman MA, Buckley DJ, et al. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother. 2003;52(10):638–642.
   PubMed Web of Science ®Google Scholar
• Roberts AI, Lee L, Schwarz E, et al. Cutting edge: NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol. 2001;167(10):5527–5530. doi:10.4049/jimmunol.167.10.5527.
   PubMed Web of Science ®Google Scholar
• Groh V, Bahram S, Bauer S, et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA. 1996;93(22):12445–12450. doi:10.1073/pnas.93.22.12445.
   PubMed Web of Science ®Google Scholar
• Groh V, Steinle A, Bauer S, et al. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998;279(5357):1737–1740. doi:10.1126/science.279.5357.1737.
   PubMed Web of Science ®Google Scholar
• Pende D, Rivera P, Marcenaro S, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 2002;62(21):6178–6186.
   PubMed Web of Science ®Google Scholar
• Dhar P, Wu J. NKG2D and its ligands in cancer. Curr Opin Immunol. 2018;51:55–61. doi:10.1016/j.coi.2018.02.004.
   PubMed Web of Science ®Google Scholar
• Roshani R, Boroujerdnia MG, Talaiezadeh AH, et al. Assessment of changes in expression and presentation of NKG2D under influence of MICA serum factor in different stages of breast cancer. Tumor Biol. 2016;37(5):6953–6962.
   PubMedGoogle Scholar
• Hilpert J, Grosse-Hovest L, Grünebach F, et al. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol. 2012;189(3):1360–1371.
   PubMed Web of Science ®Google Scholar
• Raffaghello L, Prigione I, Airoldi I, et al. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004;6(5):558–568. doi:10.1593/neo.04316.
   PubMed Web of Science ®Google Scholar
• Chen D, Gyllensten U. MICA polymorphism: biology and importance in cancer. Carcinogenesis 2014;35(12):2633–2642. doi:10.1093/carcin/bgu215.
   PubMed Web of Science ®Google Scholar
• Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141(1):52–67. doi:10.1016/j.cell.2010.03.015.
   PubMed Web of Science ®Google Scholar
• Pham D-H, Kim J-S, Kim S-K, et al. Effects of ADAM10 and ADAM17 inhibitors on natural killer cell expansion and antibody-dependent cellular cytotoxicity against breast cancer cells in vitro. Anticancer Res. 2017;37(10):5507–5513. doi:10.21873/anticanres.11981.
   PubMed Web of Science ®Google Scholar
• Radisky ES, Radisky D. Matrix metalloproteinases as breast cancer drivers and therapeutic targets. Front Biosci (Landmark Ed). 2015;20:1144–1163. doi:10.2741/4364.
   PubMed Web of Science ®Google Scholar
• Boutet P, Agüera-González S, Atkinson S, et al. Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol. 2009;182(1):49–53. doi:10.4049/jimmunol.182.1.49.
   PubMed Web of Science ®Google Scholar
• Romee R, Foley B, Lenvik T, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 2013;121(18):3599–3608.
   PubMed Web of Science ®Google Scholar
• Fingleton B, Vargo-Gogola T, Crawford HC, et al. Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 2001;3(6):459–468. doi:10.1038/sj.neo.7900190.
   PubMed Web of Science ®Google Scholar
• Lendeckel U, Kohl J, Arndt M, et al. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol. 2005;131(1):41–48. doi:10.1007/s00432-004-0619-y.
   PubMed Web of Science ®Google Scholar
• Schlecker E, Fiegler N, Arnold A, et al. Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell–activating receptor NKp30. Cancer Res. 2014;74(13):3429–3440.
   PubMed Web of Science ®Google Scholar
• Oria VO, Lopatta P, Schilling O. The pleiotropic roles of ADAM9 in the biology of solid tumors. Cell Mol Life Sci. 2018;75(13):2291–2301. doi:10.1007/s00018-018-2796-x.
   PubMed Web of Science ®Google Scholar
• Têtu B, Brisson J, Wang CS, et al. The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res. 2006;8(3):R28. doi:10.1186/bcr1503.
   PubMed Web of Science ®Google Scholar
• Liu W-H, Chang L-S. Fas/FasL-dependent and -independent activation of caspase-8 in doxorubicin-treated human breast cancer MCF-7 cells: ADAM10 down-regulation activates Fas/FasL signaling pathway. Int J Biochem Cell Biol. 2011;43(12):1708–1719. doi:10.1016/j.biocel.2011.08.004.
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Yu WH, Poulaki V, et al. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. 2001;61(2):577–581.
   PubMed Web of Science ®Google Scholar
• Jing Y, Ni Z, Wu J, et al. Identification of an ADAM17 cleavage region in human CD16 (FcγRIII) and the engineering of a non-cleavable version of the receptor in NK cells. PLoS One 2015;10(3):e0121788. doi:10.1371/journal.pone.0121788.
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Goehlsdorf D, Gieseke F, et al. Tumor-associated MICA is shed by ADAM proteases. Cancer Res. 2008;68(15):6368–6376. doi:10.1158/0008-5472.CAN-07-6768.
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res. 2006;66(5):2520–2526. doi:10.1158/0008-5472.CAN-05-2520.
   PubMed Web of Science ®Google Scholar
• Carson WE, Parihar R, Lindemann MJ, et al. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur. J. Immunol. 2001;31(10):3016–3025.
   PubMed Web of Science ®Google Scholar
• Nagler A, Lanier LL, Phillips JH. Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo. J Exp Med. 1990;171(5):1527–1533. doi:10.1084/jem.171.5.1527.
   PubMed Web of Science ®Google Scholar
• Konjević G, Spuzić IJN. Stage dependence of NK cell activity and its modulation by interleukin 2 in patients with breast cancer. Neoplasma 1993;40(2):81–85.
   PubMed Web of Science ®Google Scholar
• Al-Ghurabi BH. IL-2 and IL-4 serum levels in breast cancer. J Fac Med Baghdad. 2009;51(3):300.
   Google Scholar
• Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol. 2012;13(8):722–728. doi:10.1038/ni.2366.
   PubMed Web of Science ®Google Scholar
• Haicheur N, Escudier B, Dorval T, et al. Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients. Clin Exp Immunol. 2000;119(1):28–37. doi:10.1046/j.1365-2249.2000.01112.x.
   PubMed Web of Science ®Google Scholar
• Merendino RA, Gangemi S, Misefari A, et al. Interleukin-12 and interleukin-10 production by mononuclear phagocytic cells from breast cancer patients. Immunol Lett. 1999;68(2–3):355–358.
   PubMed Web of Science ®Google Scholar
• Choi SS, Chhabra VS, Nguyen QH, et al. Interleukin-15 enhances cytotoxicity, receptor expression, and expansion of neonatal natural killer cells in long-term culture. Clin Diagn Lab Immunol. 2004;11(5):879–888. doi:10.1128/CDLI.11.5.879-888.2004.
   PubMedGoogle Scholar
• Gillgrass AE, Chew MV, Krneta T, et al. Overexpression of IL-15 promotes tumor destruction via NK1. 1+ cells in a spontaneous breast cancer model. BMC Cancer 2015;15(1):1–15.
   PubMedGoogle Scholar
• Zhu L, Kalimuthu S, Oh JM, et al. Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 priming. Biomaterials 2019;190–191:38–50. doi:10.1016/j.biomaterials.2018.10.034.
   PubMed Web of Science ®Google Scholar
• Park IH, Yang HN, Lee KJ, et al. Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer. Oncotarget 2017;8(20):32722–32730. doi:10.18632/oncotarget.16281.
   PubMedGoogle Scholar
• van de Wetering D, de Paus RA, van Dissel JT, et al. IL-23 modulates CD56+/CD3- NK cell and CD56+/CD3+ NK-like T cell function differentially from IL-12. Int Immunol. 2009;21(2):145–153. doi:10.1093/intimm/dxn132.
   PubMed Web of Science ®Google Scholar
• Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev. 2006;17(5):325–337. doi:10.1016/j.cytogfr.2006.07.002.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Li Y, Lian J, et al. TNF-α-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer. J Transl Med. 2019;17(1):165. doi:10.1186/s12967-019-1917-0.
   PubMed Web of Science ®Google Scholar
• Ma Y, Ren Y, Dai Z-J, et al. IL-6, IL-8 and TNF-alpha levels correlate with disease stage in breast cancer patients. Adv Clin Exp Med. 2017;26(3):421–426.
   PubMed Web of Science ®Google Scholar
• Ni L, Lu J. Interferon gamma in cancer immunotherapy. Cancer Med. 2018;7(9):4509–4516. doi:10.1002/cam4.1700.
   PubMed Web of Science ®Google Scholar
• Borj MR, Andalib AR, Mohammadi A, et al. Evaluation of IL-4, IL-17, and IFN-γ levels in patients with breast cancer. Int J Basic Sci Med. 2017;2(1):20–24.
   Google Scholar
• O'Sullivan T, Saddawi-Konefka R, Gross E, et al. Interleukin-17D mediates tumor rejection through recruitment of natural killer cells. Cell Rep. 2014;7(4):989–998.
   PubMed Web of Science ®Google Scholar
• Qian X, Chen H, Wu X, et al. Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis. Cytokine 2017;89:34–44. doi:10.1016/j.cyto.2015.09.011.
   PubMed Web of Science ®Google Scholar
• Nalbant A. IL-17, IL-21, and IL-22 cytokines of T helper 17 cells in cancer. J Interferon Cytokine Res. 2019;39(1):56–60. doi:10.1089/jir.2018.0057.
   PubMed Web of Science ®Google Scholar
• Seo H, Jeon I, Kim BS, et al. IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours. Nat Commun. 2017;8(1):1–14.
   PubMedGoogle Scholar
• Ziblat A, Nuñez SY, Raffo Iraolagoitia XL, et al. Interleukin (IL)-23 stimulates IFN-γ secretion by CD56bright natural killer cells and enhances IL-18-driven dendritic cells activation. Front Immunol. 2017;8:1959. doi:10.3389/fimmu.2017.01959.
   PubMed Web of Science ®Google Scholar
• Gangemi S, Minciullo P, Adamo B, et al. Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. J Cell Biochem. 2012;113(6):2122–2125.
   PubMed Web of Science ®Google Scholar
• Khodadadi A, Razmkhah M, Eskandari A-R, et al. IL-23/IL-27 ratio in peripheral blood of patients with breast cancer. Iran J Med Sci. 2014;39(4):350–356.
   PubMedGoogle Scholar
• Zwirner NW, Ziblat A. Regulation of NK cell activation and effector functions by the IL-12 family of cytokines: the case of IL-27. Front Immunol. 2017;8:25. doi:10.3389/fimmu.2017.00025.
   PubMed Web of Science ®Google Scholar
• Kundu N, Beaty TL, Jackson MJ, et al. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst. 1996;88(8):536–541. doi:10.1093/jnci/88.8.536.
   PubMedGoogle Scholar
• Changkija B, Konwar R. Role of interleukin-10 in breast cancer. Breast Cancer Res Treat. 2012;133(1):11–21. doi:10.1007/s10549-011-1855-x.
   PubMed Web of Science ®Google Scholar
• Petersson M, Charo J, Salazar-Onfray F, et al. Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J Immunol. 1998;161(5):2099–2105.
   PubMed Web of Science ®Google Scholar
• Mocellin S, Panelli MC, Wang E, et al. The dual role of IL-10. Trends Immunol. 2003;24(1):36–43.
   PubMed Web of Science ®Google Scholar
• Kozłowski L, Zakrzewska P, Tokajuk P, et al. Concentration of interleukin-6 (Il-6), interleukin-8 (Il-8) and interleukin-10 (Il-10) in blood serum of breast cancer patients. Roczniki Akad Medycznej Bialymstoku (1995) 2003;48:82–84.
   PubMedGoogle Scholar
• Lv Z, Liu M, Shen J, et al. Association of serum interleukin‐10, interleukin‐17A and transforming growth factor‐α levels with human benign and malignant breast diseases. Exp Ther Med. 2018;15(6):5475–5480.
   PubMed Web of Science ®Google Scholar
• Joffroy CM, Buck MB, Stope MB, et al. Antiestrogens induce transforming growth factor β–mediated immunosuppression in breast cancer. Cancer Res. 2010;70(4):1314–1322.
   PubMed Web of Science ®Google Scholar
• Allan DSJ, Rybalov B, Awong G, et al. TGF-β affects development and differentiation of human natural killer cell subsets. Eur J Immunol. 2010;40(8):2289–2295. doi:10.1002/eji.200939910.
   PubMed Web of Science ®Google Scholar
• Slattery K, Zaiatz-Bittencourt V, Woods E, et al. TGFβ drives mitochondrial dysfunction in peripheral blood NK cells during metastatic breast cancer. bioRxiv 2019;648501.
   Google Scholar
• Donatelli SS, Zhou J-M, Gilvary DL, et al. TGF-β–inducible microRNA-183 silences tumor-associated natural killer cells. Proc Natl Acad Sci USA. 2014;111(11):4203–4208.
   PubMed Web of Science ®Google Scholar
• Trotta R, Dal Col J, Yu J, et al. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol. 2008;181(6):3784–3792. doi:10.4049/jimmunol.181.6.3784.
   PubMed Web of Science ®Google Scholar
• Sheen-Chen SM, Chen HS, Sheen CW, et al. Serum levels of transforming growth factor beta1 in patients with breast cancer. Arch Surg. 2001;136(8):937–940. doi:10.1001/archsurg.136.8.937.
   PubMedGoogle Scholar
• Nanni P, Nicoletti G, De Giovanni C, et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med. 2001;194(9):1195–1205. doi:10.1084/jem.194.9.1195.
   PubMed Web of Science ®Google Scholar
• Hyodo Y, Matsui K, Hayashi N, et al. IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor. J Immunol. 1999;162(3):1662–1668.
   PubMed Web of Science ®Google Scholar
• Gately MK, Renzetti LM, Magram J, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol. 1998;16:495–521. doi:10.1146/annurev.immunol.16.1.495.
   PubMed Web of Science ®Google Scholar
• Yao L, Sgadari C, Furuke K, et al. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 1999;93(5):1612–1621.
   PubMed Web of Science ®Google Scholar
• Castro F, Cardoso AP, Gonçalves RM, et al. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol. 2018;9:847. doi:10.3389/fimmu.2018.00847.
   PubMed Web of Science ®Google Scholar
• Singh S, Kumar S, Srivastava RK, et al. Loss of ELF5-FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-γ signalling. Nat Cell Biol. 2020;22(5):591–602. doi:10.1038/s41556-020-0495-y.
   PubMed Web of Science ®Google Scholar
• He Y-F, Wang X-H, Zhang G-M, et al. Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy. Cancer Immunol Immunother. 2005;54(9):891–897. doi:10.1007/s00262-004-0654-1.
   PubMed Web of Science ®Google Scholar
• Mandai M, Hamanishi J, Abiko K, et al. Dual faces of IFNγ in cancer progression: a role of PD-L1 induction in the determination of Pro- and Antitumor Immunity. Clin Cancer Res. 2016;22(10):2329–2334. doi:10.1158/1078-0432.CCR-16-0224.
   PubMed Web of Science ®Google Scholar
• Mojic M, Takeda K, Hayakawa Y. The dark side of IFN-γ: its role in promoting cancer immunoevasion. IJMS. 2017;19(1):89.
   Google Scholar
• Cornetta K, Berebitsky D, Behnia M, et al. A retroviral vector expressing human interferon gamma upregulates MHC antigen expression in human breast cancer and leukemia cell lines. Cancer Gene Ther. 1994;1(2):91–98.
   PubMed Web of Science ®Google Scholar
• Abiko K, Matsumura N, Hamanishi J, et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015;112(9):1501–1509.
   PubMed Web of Science ®Google Scholar
• Mocellin S, Panelli M, Wang E, et al. IL-10 stimulatory effects on human NK cells explored by gene profile analysis. Genes Immun. 2004;5(8):621–630. doi:10.1038/sj.gene.6364135.
   PubMed Web of Science ®Google Scholar
• Venetsanakos E, Beckman I, Bradley J, et al. High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. Br J Cancer. 1997;75(12):1826–1830. doi:10.1038/bjc.1997.311.
   PubMed Web of Science ®Google Scholar
• Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6(7):506–520. doi:10.1038/nrc1926.
   PubMed Web of Science ®Google Scholar
• de Jong JS, van Diest PJ, van der Valk P, et al. Expression of growth factors, growth‐inhibiting factors, and their receptors in invasive breast cancer. II: correlations with proliferation and angiogenesis. J Pathol. 1998;184(1):53–57. doi:10.1002/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7.
   PubMed Web of Science ®Google Scholar
• De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol. 2003;200(4):429–447. doi:10.1002/path.1398.
   PubMed Web of Science ®Google Scholar
• Carrega P, Morandi B, Costa R, et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer 2008;112(4):863–875. doi:10.1002/cncr.23239.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Ménard C, Terme M, et al. CD4 + CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med. 2005;202(8):1075–1085. doi:10.1084/jem.20051511.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Massagué J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005;8(5):369–380. doi:10.1016/j.ccr.2005.10.012.
   PubMed Web of Science ®Google Scholar
• Vitale M, Bottino C, Sivori S, et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med. 1998;187(12):2065–2072. doi:10.1084/jem.187.12.2065.
   PubMed Web of Science ®Google Scholar
• Castriconi R, Cantoni C, Della Chiesa M, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA. 2003;100(7):4120–4125. doi:10.1073/pnas.0730640100.
   PubMed Web of Science ®Google Scholar
• Hegmans JPJJ, Bard MPL, Hemmes A, et al. Proteomic analysis of exosomes secreted by human mesothelioma cells. Am J Pathol. 2004;164(5):1807–1815.
   PubMed Web of Science ®Google Scholar
• Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569–579. doi:10.1038/nri855.
   PubMed Web of Science ®Google Scholar
• Liu C, Yu S, Zinn K, et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol. 2006;176(3):1375–1385. doi:10.4049/jimmunol.176.3.1375.
   PubMed Web of Science ®Google Scholar
• O'Brien K, Rani S, Corcoran C, et al. Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. Eur J Cancer. 2013;49(8):1845–1859.
   PubMed Web of Science ®Google Scholar
• Singh R, Pochampally R, Watabe K, et al. Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer. Mol Cancer. 2014;13:256. doi:10.1186/1476-4598-13-256.
   PubMed Web of Science ®Google Scholar
• Luga V, Zhang L, Viloria-Petit AM, et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell 2012;151(7):1542–1556. doi:10.1016/j.cell.2012.11.024.
   PubMed Web of Science ®Google Scholar
• Battke C, Ruiss R, Welsch U, et al. Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC. Cancer Immunol Immunother. 2011;60(5):639–648. doi:10.1007/s00262-011-0979-5.
   PubMed Web of Science ®Google Scholar
• Tajima A, Tanaka T, Ebata T, et al. Blastocyst MHC, a putative murine homologue of HLA-G, protects TAP-deficient tumor cells from natural killer cell-mediated rejection in vivo. J Immunol. 2003;171(4):1715–1721. doi:10.4049/jimmunol.171.4.1715.
   PubMed Web of Science ®Google Scholar
• Taylor D, Gercel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer. 2005;92(2):305–311. doi:10.1038/sj.bjc.6602316.
   PubMed Web of Science ®Google Scholar
• Lin J-X, Leonard WJ. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene 2000;19(21):2566–2576. doi:10.1038/sj.onc.1203523.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Kawahara A, Fujii H, et al. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science 1994;266(5187):1045–1047. doi:10.1126/science.7973659.
   PubMed Web of Science ®Google Scholar
• Chen W, Jiang J, Xia W, et al. Tumor-related exosomes contribute to tumor-promoting microenvironment: an immunological perspective. J Immunol Res. 2017;2017:1073947.
   PubMed Web of Science ®Google Scholar
• Clayton A, Tabi Z. Exosomes and the MICA-NKG2D system in cancer. Blood Cells Mol Dis. 2005;34(3):206–213. doi:10.1016/j.bcmd.2005.03.003.
   PubMed Web of Science ®Google Scholar
• Xiang X, Poliakov A, Liu C, et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer 2009;124(11):2621–2633. doi:10.1002/ijc.24249.
   PubMed Web of Science ®Google Scholar
• Buschow SI, van Balkom BWM, Aalberts M, et al. MHC class II-associated proteins in B-cell exosomes and potential functional implications for exosome biogenesis. Immunol Cell Biol. 2010;88(8):851–856. doi:10.1038/icb.2010.64.
   PubMed Web of Science ®Google Scholar
• Soung Y, Ford S, Zhang V, et al. Exosomes in cancer diagnostics. Cancers (Basel) 2017;9(12):8.
   Google Scholar
• Harris DA, Patel SH, Gucek M, et al. Exosomes released from breast cancer carcinomas stimulate cell movement. PLoS One 2015;10(3):e0117495. doi:10.1371/journal.pone.0117495.
   PubMed Web of Science ®Google Scholar
• Jabbari N, Akbariazar E, Feqhhi M, et al. Breast cancer-derived exosomes: tumor progression and therapeutic agents. J Cell Physiol. 2020;235(10):6345–6356.
   PubMed Web of Science ®Google Scholar
• Nassar FJ, Chamandi G, Tfaily MA, et al. Peripheral blood-based biopsy for breast cancer risk prediction and early detection. Front Med (Lausanne). 2020;7:28. doi:10.3389/fmed.2020.00028.
   PubMed Web of Science ®Google Scholar
• Xu SJ, Hu HT, Li HL, et al. The role of miRNAs in immune cell development, immune cell activation, and tumor immunity: with a focus on macrophages and natural killer. Cells 2019;8(10):1140.
   Web of Science ®Google Scholar
• Espinoza JL, Takami A, Yoshioka K, et al. Human microRNA-1245 downregulates the NKG2D receptor in NK cells and impairs NKG2D-mediated functions. Haematologica 2012;97(9):1295–1303.
   PubMed Web of Science ®Google Scholar
• Zhao F-l, Dou Y-c, Wang X-f, et al. Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer. Mol Biol Rep. 2014;41(9):5913–5922. doi:10.1007/s11033-014-3466-1.
   PubMed Web of Science ®Google Scholar
• Wang B, Wang Q, Wang Z, et al. Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells. Cancer Res. 2014;74(20):5746–5757.
   PubMed Web of Science ®Google Scholar
• Zhu S-Y, Wu Q-Y, Zhang C-X, et al. miR-20a inhibits the killing effect of natural killer cells to cervical cancer cells by downregulating RUNX1. Biochem Biophys Res Commun. 2018;505(1):309–316. doi:10.1016/j.bbrc.2018.09.102.
   PubMed Web of Science ®Google Scholar
• Zhang J, Han X, Hu X, et al. IDO1 impairs NK cell cytotoxicity by decreasing NKG2D/NKG2DLs via promoting miR-18a. Mol Immunol. 2018;103:144–155. doi:10.1016/j.molimm.2018.09.011.
   PubMed Web of Science ®Google Scholar
• Breunig C, Pahl J, Küblbeck M, et al. MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells. Cell Death Dis. 2017;8(8):e2973. doi:10.1038/cddis.2017.364.
   PubMedGoogle Scholar
• Nicolini A, Ferrari P, Fini M, et al. Stem cells: their role in breast cancer development and resistance to treatment. Curr Pharm Biotechnol. 2011;12(2):196–205. doi:10.2174/138920111794295657.
   PubMed Web of Science ®Google Scholar
• Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008;10(2):R25. doi:10.1186/bcr1982.
   PubMed Web of Science ®Google Scholar
• Dontu G, Jackson KW, McNicholas E, et al. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004;6(6):R605–R615. doi:10.1186/bcr920.
   PubMed Web of Science ®Google Scholar
• Iliopoulos D, Jaeger SA, Hirsch HA, et al. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell. 2010;39(4):493–506. doi:10.1016/j.molcel.2010.07.023.
   PubMed Web of Science ®Google Scholar
• Korkaya H, Paulson A, Charafe-Jauffret E, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009;7(6):e1000121. doi:10.1371/journal.pbio.1000121.
   PubMed Web of Science ®Google Scholar
• Liu S, Dontu G, Mantle ID, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006;66(12):6063–6071. doi:10.1158/0008-5472.CAN-06-0054.
   PubMed Web of Science ®Google Scholar
• Ma X-J, Dahiya S, Richardson E, et al. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 2009;11(1):R7. doi:10.1186/bcr2222.
   PubMed Web of Science ®Google Scholar
• Vahidian F, Duijf PHG, Safarzadeh E, et al. Interactions between cancer stem cells, immune system and some environmental components: friends or foes? Immunol Lett. 2019;208:19–29. doi:10.1016/j.imlet.2019.03.004.
   PubMed Web of Science ®Google Scholar
• Sceneay J, Chow MT, Chen A, et al. Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G + immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res. 2012;72(16):3906–3911. doi:10.1158/0008-5472.CAN-11-3873.
   PubMed Web of Science ®Google Scholar
• Balsamo M, Scordamaglia F, Pietra G, et al. Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci USA. 2009;106(49):20847–20852. doi:10.1073/pnas.0906481106.
   PubMed Web of Science ®Google Scholar
• Morales JK, Kmieciak M, Knutson KL, et al. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat. 2010;123(1):39–49. doi:10.1007/s10549-009-0622-8.
   PubMed Web of Science ®Google Scholar
• Pietras K, Östman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res. 2010;316(8):1324–1331. doi:10.1016/j.yexcr.2010.02.045.
   PubMed Web of Science ®Google Scholar
• Li H, Han Y, Guo Q, et al. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol. 2009;182(1):240–249. doi:10.4049/jimmunol.182.1.240.
   PubMed Web of Science ®Google Scholar
• Sinha P, Clements VK, Bunt SK, et al. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol. 2007;179(2):977–983. doi:10.4049/jimmunol.179.2.977.
   PubMed Web of Science ®Google Scholar
• Corzo CA, Condamine T, Lu L, et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207(11):2439–2453. doi:10.1084/jem.20100587.
   PubMed Web of Science ®Google Scholar
• Chiesa MD, Carlomagno S, Frumento G, et al. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46-and NKG2D-activating receptors and regulates NK-cell function. 2006;108(13):4118–4125.
   Google Scholar
• Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol. 2019;12(1):76. doi:10.1186/s13045-019-0760-3.
   PubMed Web of Science ®Google Scholar
• Zhou J, Tang Z, Gao S, et al. Tumor-associated macrophages: recent insights and therapies. Front Oncol. 2020;10:188. doi:10.3389/fonc.2020.00188.
   PubMed Web of Science ®Google Scholar
• Baginska J, Viry E, Paggetti J, et al. The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front Immunol. 2013;4:490. doi:10.3389/fimmu.2013.00490.
   PubMed Web of Science ®Google Scholar
• Luo Y, Zhou H, Krueger J, et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest. 2006;116(8):2132–2141. doi:10.1172/JCI27648.
   PubMed Web of Science ®Google Scholar
• Bingle á, Brown N, Lewis C. The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196(3):254–265. doi:10.1002/path.1027.
   PubMed Web of Science ®Google Scholar
• Leek RD, Harris AL. Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia. 2002;7(2):177–189.
   PubMed Web of Science ®Google Scholar
• Saio M, Radoja S, Marino M, et al. Tumor-infiltrating macrophages induce apoptosis in activated CD8(+) T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide. J Immunol. 2001;167(10):5583–5593. doi:10.4049/jimmunol.167.10.5583.
   PubMed Web of Science ®Google Scholar
• Krneta T, Gillgrass A, Poznanski S, et al. M2-polarized and tumor-associated macrophages alter NK cell phenotype and function in a contact-dependent manner. J Leukoc Biol. 2017;101(1):285–295. doi:10.1189/jlb.3A1215-552R.
   PubMed Web of Science ®Google Scholar
• Burke B, Giannoudis A, Corke KP, et al. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol. 2003;163(4):1233–1243.
   PubMed Web of Science ®Google Scholar
• Brown JM, Recht L, Strober S. The promise of targeting macrophages in cancer therapy. Clin Cancer Res. 2017;23(13):3241–3250. doi:10.1158/1078-0432.CCR-16-3122.
   PubMed Web of Science ®Google Scholar
• Jeong H, Hwang I, Kang SH, et al. Tumor-associated macrophages as potential prognostic biomarkers of invasive breast cancer. J Breast Cancer. 2019;22(1):38–51. doi:10.4048/jbc.2019.22.e5.
   PubMed Web of Science ®Google Scholar
• Hansell CAH, Fraser AR, Hayes AJ, et al. The atypical chemokine receptor Ackr2 constrains NK cell migratory activity and promotes metastasis. J Immunol. 2018;201(8):2510–2519.
   PubMed Web of Science ®Google Scholar
• Sjoberg E, Meyrath M, Chevigné A, et al. The diverse and complex roles of atypical chemokine receptors in cancer: from molecular biology to clinical relevance and therapy. Adv Cancer Res. 2020;145:99–138.
   PubMed Web of Science ®Google Scholar
• Parodi M, Raggi F, Cangelosi D, et al. Hypoxia modifies the transcriptome of human NK cells, modulates their immunoregulatory profile, and influences NK cell subset migration. Front Immunol. 2018;9:2358. doi:10.3389/fimmu.2018.02358.
   PubMed Web of Science ®Google Scholar
• Beavis PA, Divisekera U, Paget C, et al. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci USA. 2013;110(36):14711–14716.
   PubMed Web of Science ®Google Scholar
• Baginska J, Viry E, Berchem G, et al. Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. Proc Natl Acad Sci USA. 2013;110(43):17450–17455.
   PubMed Web of Science ®Google Scholar
• Jiang XP, Elliott RL, Head JF. Manipulation of iron transporter genes results in the suppression of human and mouse mammary adenocarcinomas. Anticancer Res. 2010;30(3):759–765.
   PubMed Web of Science ®Google Scholar
• Jiang X-P, Elliott RL. Decreased iron in cancer cells and their microenvironment improves cytolysis of breast cancer cells by natural killer cells. Anticancer Res. 2017;37(5):2297–2305. doi:10.21873/anticanres.11567.
   PubMed Web of Science ®Google Scholar
• Miller LD, Coffman LG, Chou JW, et al. An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res. 2011;71(21):6728–6737. doi:10.1158/0008-5472.CAN-11-1870.
   PubMed Web of Science ®Google Scholar
• Verma C, Kaewkangsadan V, Eremin JM, et al. Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery. J Transl Med. 2015;13(1):180. doi:10.1186/s12967-015-0535-8.
   PubMedGoogle Scholar
• Zitvogel L, Tesniere A, Apetoh L, et al. [Immunological aspects of anticancer chemotherapy]. Bull Acad Natl Med. 2008;192(7):1469.
   PubMed Web of Science ®Google Scholar
• Muraro E, Comaro E, Talamini R, et al. Improved natural killer cell activity and retained anti-tumor CD8+ T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy. J Transl Med. 2015;13(1):1–14.
   PubMedGoogle Scholar
• Muntasell A, et al. High numbers of circulating CD57+ NK cells associate with resistance to HER2-specific therapeutic antibodies in HER2+ primary breast cancer. Cancer Immunol Res. 2019;7(8):1280–1292.
   PubMed Web of Science ®Google Scholar
• Garcia-Chagollan M, Carranza-Torres IE, Carranza-Rosales P, et al. Expression of NK cell surface receptors in breast cancer tissue as predictors of resistance to antineoplastic treatment. Technol Cancer Res Treat. 2018;17:1533033818764499. doi:10.1177/1533033818764499.
   Web of Science ®Google Scholar
• Rothammer A, Sage EK, Werner C, et al. Increased heat shock protein 70 (Hsp70) serum levels and low NK cell counts after radiotherapy - potential markers for predicting breast cancer recurrence? Radiat Oncol. 2019;14(1):78. doi:10.1186/s13014-019-1286-0.
   PubMedGoogle Scholar
• Reim F, Dombrowski Y, Ritter C, et al. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res. 2009;69(20):8058–8066. doi:10.1158/0008-5472.CAN-09-0834.
   PubMed Web of Science ®Google Scholar
• Ascierto ML, et al. A signatures of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat. 2012;131(3):871–880.
   PubMed Web of Science ®Google Scholar
• Lorenzo-Herrero S, López-Soto A, Sordo-Bahamonde C, et al. NK cell-based immunotherapy in cancer metastasis. Cancers. 2018;11(1):29.
   Web of Science ®Google Scholar
• Tallerico R, Conti L, Lanzardo S, et al. NK cells control breast cancer and related cancer stem cell hematological spread. Oncoimmunology. 2017;6(3):e1284718. doi:10.1080/2162402X.2017.1284718.
   PubMed Web of Science ®Google Scholar
• Kim R, Kawai A, Wakisaka M, et al. A potential role for peripheral natural killer cell activity induced by preoperative chemotherapy in breast cancer patients. Cancer Immunol Immunother. 2019;68(4):577–585. doi:10.1007/s00262-019-02305-z.
   PubMed Web of Science ®Google Scholar
• Liu X, Ran R, Shao B, et al. Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer. Chin J Cancer Res. 2018;30(3):315–326. doi:10.21147/j.issn.1000-9604.2018.03.04.
   PubMed Web of Science ®Google Scholar
• Hu W, Wang G, Huang D, et al. Cancer immunotherapy based on natural killer cells: current progress and new opportunities. Front Immunol. 2019;10:1205. doi:10.3389/fimmu.2019.01205.
   PubMed Web of Science ®Google Scholar
• Shenouda MM, Gillgrass A, Nham T, et al. Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours. Breast Cancer Res. 2017;19(1):76. doi:10.1186/s13058-017-0867-9.
   PubMedGoogle Scholar
• Roberti MP, Mordoh J, Levy EM. Biological role of NK cells and immunotherapeutic approaches in breast cancer. Front Immunol. 2012;3:375. doi:10.3389/fimmu.2012.00375.
   PubMed Web of Science ®Google Scholar
• Li Y, Sun R. Tumor immunotherapy: new aspects of natural killer cells. Chin J Cancer Res. 2018;30(2):173–196. doi:10.21147/j.issn.1000-9604.2018.02.02.
   PubMed Web of Science ®Google Scholar
• Liang S, Xu K, Niu L, et al. Comparison of autogeneic and allogeneic natural killer cells immunotherapy on the clinical outcome of recurrent breast cancer. Onco Targets Ther. 2017;10:4273–4281. doi:10.2147/OTT.S139986.
   PubMed Web of Science ®Google Scholar
• Gras Navarro A, Bjorklund AT, Chekenya M. Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol. 2015;6:202. doi:10.3389/fimmu.2015.00202.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kim Y-A, Sim CK, et al. Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer. Oncotarget. 2017;8(69):113345–113359. doi:10.18632/oncotarget.23007.
   PubMedGoogle Scholar